The three-year signature initiative is designed to make learning about health and disease engaging, accessible, and exciting for students in grades 6-8, primarily in under-resourced schools across the country.
The programme will kick off with a Virtual Field Trip to AstraZeneca's Gaithersburg, MD, research laboratories, which will premiere on Tuesday, October 8, 2019 at 1:00 p.m. ET / 10:00 a.m. PT.
The programme, Generation Health: How Science Powers Us, will provide students first-hand access to the technology and scientists working to create medical breakthroughs for the world's most pressing health problems. Educators, parents and students are invited to register here.
Participants are encouraged to join a live Twitter chat during the premiere by submitting questions and sending pictures using #GenerationHealthVFT.
Generation Health: How Science Powers Us will provide hands-on, standards-aligned STEM learning activities where students investigate both preventative measures and innovative solutions to key health concerns in the areas of oncology, cardiovascular, and respiratory disease.
The programme will also offer resources for employee engagement in the classroom.
As part of this program, Generation Health provides a suite of educational resources, including, Learning Undefeated's Drop Anywhere Labs, custom-outfitted STEM learning spaces built from modified shipping containers.
These light, easy-to-access and inexpensive labs provide a range of career and skills education for middle school students, as well as flexible in-classroom resources that empower teachers and enables them to serve up to four classes simultaneously.
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder
WuXi AppTec's Nantong site receives 2025 Architizer A+Award
MGI partners with Negedia to enhance genomic sequencing in Italy
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress